Last reviewed · How we verify
HRS-2129
At a glance
| Generic name | HRS-2129 |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis (PHASE1)
- A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain (PHASE1)
- Clinical Study of HRS-2129 for Postoperative Analgesia in Orthopaedics (PHASE1, PHASE2)
- A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery (PHASE2, PHASE3)
- A Multiple Ascending Dose Trial of HRS-2129 in Healthy Subjects (PHASE1)
- A Single Dose Escalation Trial of HRS-2129 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-2129 CI brief — competitive landscape report
- HRS-2129 updates RSS · CI watch RSS
- Shandong Suncadia Medicine Co., Ltd. portfolio CI